Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Cilansetron – New Treatment for IBS

Solvay SA, with headquarters in Brussels, Belgium, was developing Cilansetron, a 5-HT3 antagonist indicated for the treatment of diarrhoea-predominant irritable bowel syndrome (IBS).



Go Top